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Hookworms infect 730 million people in developing countries where they are a leading cause
of intestinal blood loss and iron-deficiency anemia. At the site of attachment to the host, adult
hookworms ingest blood and lyse the erythrocytes to release hemoglobin. The parasites
subsequently digest hemoglobin in their intestines using a cascade of proteolysis that begins
with the Ancylostoma caninum aspartic protease 1, APR-1.
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We show that vaccination of dogs with recombinant Ac-APR-1 induced antibody and cellular
responses and resulted in significantly reduced hookworm burdens (p ¼ 0.056) and fecal egg
counts (p ¼ 0.018) in vaccinated dogs compared to control dogs after challenge with infective
larvae of A. caninum. Most importantly, vaccinated dogs were protected against blood loss (p ¼
0.049) and most did not develop anemia, the major pathologic sequela of hookworm disease.
IgG from vaccinated animals decreased the catalytic activity of the recombinant enzyme in vitro
and the antibody bound in situ to the intestines of worms recovered from vaccinated dogs,
implying that the vaccine interferes with the parasite’s ability to digest blood.

Conclusion
To the best of our knowledge, this is the first report of a recombinant vaccine from a
hematophagous parasite that significantly reduces both parasite load and blood loss, and it
supports the development of APR-1 as a human hookworm vaccine.
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01; ELISA, enzyme-linked
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gram of feces; Hb, hemoglobin; L3,
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and particularly fetal, Hb demands are considerable, rendering these populations most vulnerable to the parasite [1].
Here we describe vaccination of dogs with the aspartic
hemoglobinase of A. caninum, Ac-APR-1 [21,23] and show that
vaccination resulted in the production of neutralizing antibodies, signiﬁcantly reduced egg counts, and signiﬁcantly
reduced adult worm burdens. Most importantly, Hb levels of
vaccinated dogs were signiﬁcantly higher than those of dogs
that were vaccinated with adjuvant alone after parasite
challenge. These data show that aspartic hemoglobinases,
particularly APR-1, are efﬁcacious vaccines against canine
hookworm disease, providing strong support for further
investigation and development of APR-1 as a recombinant
vaccine against human hookworm disease.

Introduction
Hookworms infect more than 700 million people in
tropical and subtropical regions of the world. The major
species infecting humans are Necator americanus and Ancylostoma duodenale. The parasites feed on blood, causing irondeﬁciency anemia, and as such, are a major cause of disease
burden in developing countries [1]. Unlike other human
helminthiases, worm burdens do not generally decrease with
age; in fact, recent ﬁndings revealed that the heaviest worm
burdens are found among the elderly [2,3]. Whereas
anthelminthic chemotherapy with benzimidazole drugs is
effective in eliminating existing adult parasites, re-infection
occurs rapidly after treatment [4], making a vaccine against
hookworm disease a desirable goal.
Canines can be successfully vaccinated against infection
with the dog hookworm, Ancylostoma caninum, by immunization
with third-stage infective larvae (L3) that have been attenuated with ionizing radiation [5–7]. Subsequently, varying levels
of vaccine efﬁcacy have been reported for the major antigens
secreted by hookworm L3 using hamsters [8,9] and dogs [10].
Despite obtaining encouraging levels of protection with larval
antigens, only partial reductions in parasite load (fecal egg
counts and adult worm burdens) were reported. Moreover,
protective antigens from the larval stage are only expressed by
L3, and not adult worms, rendering antibodies against these
L3 secretions useless against parasites that have successfully
reached adulthood in the gut and begun to feed on blood. We
therefore suggest that an ideal hookworm vaccine would
require a cocktail of two recombinant proteins, one targeting
the infective larva and the second targeting the blood-feeding
adult stage of the parasite [11].
Of the different families of proteins expressed by bloodfeeding parasitic helminths, proteolytic enzymes have shown
promise as intervention targets for vaccine development
[12,13]. Proteases are pivotal for a parasitic existence,
mediating fundamental physiologic processes such as molting,
tissue invasion, feeding, embryogenesis, and evasion of host
immune responses [12,14]. Parasite extracts enriched for
proteases protect sheep against the blood-feeding nematodes
Haemonchus contortus [15–18] and Ostertagia ostertagi [19]; however, signiﬁcant protective efﬁcacy has not been shown with a
puriﬁed recombinant protease from nematodes of livestock.
Hookworms feed by burying their anterior ends in the
intestinal mucosa of the host, rupturing capillaries and
ingesting the liberated blood. Erythrocytes are lysed by pore
formation [20], releasing hemoglobin (Hb) into the lumen of
the parasite’s intestine, where it is degraded by a semiordered pathway of catalysis that involves aspartic, cysteine,
and metalloproteases [21]. Vaccination of dogs with a
catalytically active recombinant cysteine hemoglobinase, AcCP-2, induced antibodies that neutralized proteolytic activity
and provided partial protection to vaccinees by reducing egg
output (a measure of intestinal worm burden) and worm size,
but signiﬁcant reductions of adult worm burdens and/or
blood loss were not observed [22]. Anemia is the primary
pathology associated with hookworm infection, and an
ultimate human hookworm vaccine would limit the amount
of blood loss caused by feeding worms and maintain normal
levels of Hb. This is particularly important in young children
as well as women of child-bearing age, in whom menstrual,
PLoS Medicine | www.plosmedicine.org

Methods
Expression of Recombinant Ac-APR-1 in Pichia pastoris
The entire open reading frame of Ac-APR-1 encoding the
zymogen (spanning Ser-17 to the C-terminal Phe-446) but
excluding the predicted signal peptide was cloned into the
expression vector pPIC-Za (Invitrogen, Carlsbad, California,
United States) using the XbaI and EcoRI sites. Yeast, P. pastoris
X 33, was transformed with the vector encoding the Ac-APR-1
zymogen as recommended by the manufacturer (Invitrogen)
with modiﬁcations. Protein disulﬁde isomerase (PDI) gene in
the vector pPIC3.5 (a gift from Mehmet Inan, University of
Nebraska, Lincoln, Nebraska, United States) was cut with SacI
and transformed into P. pastoris X 33 cells which were already
transformed with Ac-apr-1 following the manufacturer’s
instructions. Eight transformed colonies were picked from
YPD plates containing Geneticin (0.5–1.0 mgml1) and
Zeocin (1.0 mgml1) and tested for Ac-APR-1 expression
following the manufacturer’s instructions. The highest
expressing colony was selected and transferred to suspension
culture in ﬂasks containing BMG medium (buffered minimal
glycerol: 1.34% yeast nitrogen base, 0.00004% d-biotin, 1% w/
v glycerol, and 100 mM potassium phosphate, [pH 6.0]).
Suspension cultures were then transferred to a Bioﬂo 3000
fermentor (New Brunswick Scientiﬁc, Edison, New Jersey,
United States) utilizing a 5-l vessel as described [8]. The
recombinant protein was secreted into culture medium and
afﬁnity puriﬁed on nickel-agarose as described elsewhere [8].
Progress of puriﬁcation was monitored using SDS-PAGE gels
stained with Coomassie Brilliant Blue and immunoblots using
monoclonal antibodies to the vector-derived myc epitope.
Recombinant Ac-APR-1 was treated with PNGase F and Oglycosidase, according to the manufacturer’s instructions
(Enzymatic CarboRelease kit; QA-Bio, San Mateo, California,
United States), under denaturing conditions to remove any
N-linked and O-linked oligosaccharides. Deglycosylation was
performed only to conﬁrm the presence of N-linked sugars
on the recombinant molecule. All remaining studies were
conducted with the glycoprotein.

Activation and Hemoglobinolytic Activity of Recombinant
APR-1
The unactivated zymogen was used for vaccination. A small
amount of the puriﬁed protein, however, was buffer
exchanged into 100 mM sodium formate (pH 3.6)/0.15 M
NaCl using a PD10 desalting column (Amersham Biosciences,
Little Chalfont, United Kingdom) to facilitate proteolytic
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humidiﬁed 5% CO2 atmosphere at 37 8C for 2 d (ConAstimulated cultures) and 5 d (APR-1). Cells were pulsed for 6 h
with 1.0 lCi of [3H] thymidine (PerkinElmer Life And
Analytical Sciences, Boston, Massachusetts, United States)
and harvested onto glass ﬁber ﬁlters. Radioactive incorporation was determined by liquid scintillation spectrometry.
Proliferation responses were expressed as stimulation indices,
SI (where SI ¼ mean proliferation of stimulated cultures/mean
proliferation of unstimulated cultures). For cytokine analyses,
whole blood (collected as described above) was diluted 1:8 in
RPMI supplemented with 3% antibiotic/antimycotic solution
in a 48-well ﬂat-bottomed culture plate with a ﬁnal volume of
1.0 ml per well. Cells were stimulated by the addition of 25
lgml1 of recombinant APR-1. After 48 h of incubation at 37
8C, 700 ll of supernatant was removed from each well and
stored at 20 8C until required for the cytokine assay. IL-4, IL10, and IFN-c were measured using a capture ELISA assay for
dogs (R & D Systems, Minneapolis, Minnesota, United States)
following the manufacturer’s instructions. Biotin-labeled
detection antibodies were used (100 ngml1), revealed with
streptavidin-HRP (Amersham Biosciences), and plates were
developed with OPD (O-Phenylenediamine) substrate system
(Sigma-Aldrich).

activation and removal of the pro-region. One microgram of
puriﬁed, activated protease was then added to 10 lg of dog
Hb in the same buffer and incubated at 37 8C for 2 h.
Cleavage of Hb was assessed visually by staining SDS-PAGE
gels with Coomassie Brilliant Blue.

Animal Husbandry
Purpose-bred, parasite naive, male beagles aged 8 6 1 wk
were purchased from Marshall Farms (North Rose, New York,
United States), identiﬁed by ear tattoo, and maintained in the
George Washington University Animal Research Facility as
previously described [24]. The experiments were conducted
according to a protocol approved by the University Animal
Care and Use Committee (IACUC 48–12,0 [12,1]E). Before the
ﬁrst vaccination and after each subsequent one, a blood
sample was obtained from each dog.

Vaccine Study Design and Antigen-Adjuvant Formulation
The vaccine trial was designed to test Ac-APR-1 zymogen
formulated with the adjuvant AS03 [25], obtained from
GlaxoSmithKline (a kind gift from Drs. Joe Cohen and Sylvie
Cayphas; GSK Biologicals, Rixensart, Belgium). To make six
doses of Ac-APR-1 formulated with AS03, 600 lg of
recombinant protein (1.5 ml of Ac-APR-1 at a concentration
of 0.4 mgml1) was mixed with 1.2 ml of 20 mM Tris-HCl, 0.5
M NaCl (pH 7.9), and 1.5 ml of AS03; the contents of the tube
were vortex mixed for 30 sec then shaken at low speed for 10
min. Dogs were immunized with 100 lg of formulated antigen
in a ﬁnal volume of 0.5 ml. AS03-only control was prepared as
described above, with PBS included instead of Ac-APR-1.

Hb Measurements
To determine Hb concentrations of experimental dogs, 1–2
ml of blood were collected in EDTA and analyzed using a
QBC VetAutoread Hematology System and VETTEST Software (IDEXX Laboratories, Westbrook, Maine, United States).

Hookworm Infections and Parasite Recovery

Canine Immunizations and Antibody Measurements

Two weeks after the ﬁnal immunization, dogs were
anaesthetized using a combination of ketamine and xylazine
(20 mgkg1 and 10 mgkg1 respectively) and infected via the
footpad with 500 A. caninum L3 as described elsewhere [22].
Quantitative hookworm egg counts (McMaster technique)
were obtained for each dog 3 d per wk from days 12–26
postinfection. Four weeks postinfection, the dogs were killed
by intravenous injection of barbiturate, and adult hookworms
were recovered and counted from the small and large
intestines at necropsy [24]. The sex of each adult worm was
determined as described elsewhere [8]. Approximately 1–2 cm
lengths of small intestine were removed and stored in
formalin for future histopathologic analysis.

Five beagles were immunized three times with AS03formulated Ac-APR-1 by intramuscular injection. The vaccine
was administered on days 0, 21, and 42, beginning when the
dogs were 62 6 4 d of age. As negative controls, ﬁve beagles
were also injected intramuscularly with an equivalent amount
of AS03 using the identical schedule. Blood was drawn at least
once every 21 d and serum was separated from cells by
centrifugation. Enzyme-linked immunosorbent assays (ELISA) were performed as previously described [24]. Recombinant Ac-APR-1 was coated onto microtiter plates at a
concentration of 5.0 lgml1. Dog sera were titrated between
1:100 and 1:2 3 106 to determine endpoint titers (the highest
dilution of test group [APR-1] sera that gave a mean O.D. of
33 the mean optical density (OD) of sera from the control
group). Anti-canine IgG1, IgG2, and IgE antibodies conjugated to horseradish peroxidase (Bethyl Laboratories, Montgomery, Texas, United States) were used at a dilution of
1:1,000. Blood was collected from dogs before immunizations
and 7 d after the third vaccination but before L3 challenge.

Statistical Methods
In most cases, the small size of the samples did not enable
us to determine if values were normally distributed, so the
following non-parametric tests were used: Mann-Whitney U
was used to test whether two independent samples (groups)
came from the same population, and the Kruskal Wallis H test
was used to determine if several independent samples came
from the same population. Normally distributed variables
were tested in the following manner: The independentsamples t-test procedure was used to compare the means for
two groups, and an analysis of variance was used to test the
hypothesis that several means are equal, followed by a Dunnet
post hoc multiple comparison t-test to compare the vaccine
treatment groups against the control group. Differences were
considered statistically signiﬁcant if the calculated p-value
was equal to or less than 0.1 (two-sided). The percentage
reduction or increase in adult hookworm burden in the

Stimulation of and Cytokine Measurements from Cultured
Whole Blood
Lymphoproliferation assays were performed using a whole
blood microassay as previously described [26]. Brieﬂy, 25 ll of
heparinized blood was diluted in 200 ll of RPMI 1640
medium (Gibco, Invitrogen) supplemented with 3% antibiotic/antimycotic solution (Gibco). All tests were performed
in triplicate in 96-well ﬂat-bottomed culture plates using
recombinant APR-1 at a concentration of 25 lgml1 and
concanavalin A (ConA; Sigma-Aldrich, St. Louis, Missouri,
United States) at 80 lgml1. Incubation was carried out in a
PLoS Medicine | www.plosmedicine.org
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Figure 2. The Geometric Mean Titers of the IgG1 and IgG2 Antibody
Responses of Dogs Vaccinated with Recombinant Ac-APR-1 Formulated
with AS03 or AS03 Alone
LC, day on which dogs were challenged with hookworm L3; N, day of
necropsy; V1, V2, and V3, days on which animals were vaccinated.
DOI: 10.1371/journal.pmed.0020295.g002

Effect of Anti–Ac-APR-1 IgG on Proteolytic Activity
Canine IgG was puriﬁed from sera of vaccinated dogs using
protein A-agarose (Amersham Biosciences) as previously
described [23]. Puriﬁed IgG (0.2 lg) was incubated with 1.0
lg of recombinant Ac-APR-1 for 45 mins prior to assessing
catalytic activity of APR-1 against the ﬂuorogenic substrate oaminobenzoyl-IEF-nFRL-NH2 as described previously [23].
The aspartic protease inhibitor, pepstatin A, was included at
a ﬁnal concentration of 1.0 lM as a positive control for
enzymatic inhibition. Data was recorded from triplicate
experiments and presented as relative ﬂuorescence units
using a TD700 ﬂuorometer (Turner Designs, Sunnyvale,
California, United States).

Figure 1. P. pastoris Secrete Ac-APR-1 Zymogen that Autoactivates at
Low pH and Degrades Canine Hb
SDS-PAGE gel stained with Coomassie Brilliant Blue showing purification
of recombinant APR-1 zymogen from P. pastoris culture supernatant.
(A) Lane 1, molecular weight markers; lane 2, concentrated culture
supernatant; lane 3, flow-through from a nickel-IDA column; lane 4, 5
mM imidazole wash; lane 5, 20 mM imidazole column eluate; lane 6, 60
mM imidazole eluate; and lane 7, 1 M imidazole eluate. Purified
recombinant APR-1 zymogen was activated by buffer exchange into 0.1
M sodium formate/0.1 M NaCl (pH 3.6).
(B) Lane 1, molecular weight markers; lane 2, 5.0 lg of canine Hb (pH
3.6); and lane 3, 5.0 lg of canine Hb (pH 3.6) incubated with 0.2 lg of
recombinant APR-1.
DOI: 10.1371/journal.pmed.0020295.g001

Results
Secretion of Catalytically Active Ac-APR-1 by P. pastoris
Yeast secreted the APR-1 zymogen into culture medium at
an approximate concentration of 1.0 mgl1 (Figure 1A). In the
absence of co-expression with the PDI chaperone, the amount
of APR-1 secreted by P. pastoris was approximately half that
obtained here (not shown). Ac-APR-1 has one potential
glycosylation site at Asn-29 of the zymogen (after removal of
the signal peptide), and treatment with PNGase F decreased
the size of the recombinant protein by the expected size (2–3
kDa; not shown). The activated recombinant protease readily
digested canine Hb at acidic pH (Figure 1B), conﬁrming that
Ac-APR-1 expressed in yeast is catalytically active and digested
Hb with similar efﬁciency to recombinant Ac-APR-1 produced
in baculovirus (data not shown).

vaccinated group was expressed relative to the control group
as described elsewhere [24].

Immunohistochemistry
Adult hookworms were recovered at necropsy from vaccinated dogs and control dogs, washed brieﬂy, then ﬁxed and
sectioned as previously described [22]. To observe whether IgG
from vaccinated but not control dogs, bound to APR-1 lining
the intestinal microvillar surface of worms in situ, sections
were probed with Cy3-conjugated rabbit anti-dog IgG (Jackson
Immunoresearch, West Grove, Pennsylvania, United States) at
a dilution of 1:500 as described elsewhere [27]. Sections were
visualized using a Leica IM 100 inverted ﬂuorescence microscope (Leica Microsystems, Wetzlar, Germany).
PLoS Medicine | www.plosmedicine.org

Recombinant Ac-APR-1 Is Immunogenic in Dogs
AS03 was used as an adjuvant based on its ability to induce a
higher IgG1 response and greater reduction in hookworm egg
counts when used to vaccinate dogs in a head-to-head
comparison of a cysteine hemoglobinase formulated with
four different adjuvants [22]. Dogs immunized with recombinant Ac-APR-1 formulated with AS03 produced IgG1 and IgG2
antibody responses as measured by ELISA using the recombinant protein (Figure 2). IgE titers were low (,1:1,500) and
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Figure 3. Canine Cellular Immune Response to Vaccination with Recombinant Ac-APR-1
Cell proliferation of whole blood cells from vaccinated (APR-1) and control dogs (AS03) when stimulated with concanavalin A (A) or recombinant AcAPR-1 (B) before (day 0) and after the final immunization (day 51). The p-value comparing the mean differences between the vaccinated group and
controls is denoted. Detection of secreted IFN-c in whole blood cultures taken from vaccinated and control dogs before and after immunization (C).
Mean cytokine concentrations are indicated in pgml1 with standard error bars. Statistically significant differences are indicated above the bars by pvalues. APR, stimulated with recombinant APR-1; NS, non-stimulated cultures.
DOI: 10.1371/journal.pmed.0020295.g003

IL-4 or IL-10 after stimulation with APR-1 in either
vaccinated or control groups (not shown).

were not sustained past challenge. We did not adsorb IgG from
serum before measuring IgE in this study; however, in previous
trials IgG was removed and we did not see a difference in
antigen-speciﬁc IgE titers. For vaccinated dogs, maximum
IgG2 titers of 1:121,500 were attained by all ﬁve dogs after the
second vaccination. High titers persisted through challenge
and decreased to 1:26,098 by necropsy. IgG1 titers peaked at
1:13,500 after the third vaccination in all four dogs and
dropped to 1:3,600 by necropsy. Dogs immunized with
adjuvant alone did not generate detectable immune responses
greater than 1:500, even after larval challenge.
Dogs rapidly acquire resistance to hookworm with maturity. A single dog was therefore removed from the control
group (for all analyses) because its weight was greater than the
acceptable range at all time points after the ﬁrst vaccination
(mean plus or minus three standard errors).

Vaccination with Ac-APR-1 Decreases Fecundity of Female
Hookworms
Dogs develop age- and exposure-related immunity to A.
caninum [5], so we therefore observed egg counts from
vaccinated animals up to 26 d postchallenge, after which we
often observe a signiﬁcant decrease in egg counts in some
dogs. Because of daily variation in egg counts from infected
dogs (A. Loukas. S. Mendez, and P. Hotez, unpublished data),
we analyzed the data in two ways. Firstly, the median egg
counts for days 21, 23, and 26 postinfection were used to
compare worm fecundity between vaccinated and control
groups. A 70% decrease in median egg counts was observed
in dogs vaccinated with Ac-APR-1 (2,650 eggs per gram of
feces [epg]) compared with dogs that were vaccinated with
adjuvant alone (8,725 epg) when median egg counts were
calculated for the three time points measured after larval
challenge (Figure 4A). We then compared geometric mean
values of egg counts between the two groups (Figure 4B), and
showed that mean egg counts of the vaccinated animals
remained lower than the control animals as worms became
fecund by day 21, implying that fecundity of female worms
diminished signiﬁcantly as they began to feed on blood
containing anti–APR-1 antibodies. By day 26 postchallenge,
there was an 85% reduction in mean egg counts between the
two groups. For statistical analyses, we transformed egg

Vaccination Induces Antigen-Specific Cell Proliferation
and Cytokine Production
Vaccination with APR-1 induced a high level of lymphocyte/leukocyte proliferation compared with control dogs
when cells were stimulated with APR-1 (p , 0.01, t-test). Cells
from both vaccinated and control dogs proliferated equally
when stimulated with mitogen (Figure 3A and 3B). No
signiﬁcant proliferation to APR-1 was observed before the
immunization process. Immunization with APR-1 elicited
antigen-speciﬁc production of IFN-c (p ¼ 0.03, t-test) (Figure
3C). In contrast, we did not detect signiﬁcant production of
PLoS Medicine | www.plosmedicine.org
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using a Mann-Whitney test (APR-1 versus control), revealed a
statistically signiﬁcant difference (p ¼ 0.018).

Vaccination with Ac-APR-1 Significantly Reduces Adult
Hookworm Burdens
A statistically signiﬁcant difference at the p  0.1 level (p ¼
0.095; Mann-Whitney U test) was detected for a one-sided test
between median adult worm burdens recovered from
vaccinated dogs (182) compared with control dogs (270) but
not for a two-sided test (p ¼ 0.190) (Figure 5). Percentage
reduction of the median worm counts was 33% when data
from both sexes of worms were combined, 30% for male
worms (p ¼ 0.111 [2-sided] or p ¼ 0.056 [1-sided]) and 40% for
female worms (p ¼ 0.1905 [2-sided] or p ¼ 0.0952 [1-sided]),
again supporting the enhanced effect of the vaccine on
female worms given their increased nutritional requirements
for egg production.

Vaccination with APR-1 Protects against Anemia
Hb levels in four of the ﬁve dogs that were vaccinated with
APR-1 were signiﬁcantly elevated when compared with
control dogs (adjuvant alone) after challenge infection
(Figure 6). The median Hb concentration of vaccinated dogs
for the last two time points (0 and 7 d prior to necropsy) was
12.45 gdl1 compared with 9.5 gdl1 for the control dogs that
were immunized with adjuvant alone (p ¼ 0.049; MannWhitney U test). A decline in Hb levels was seen in all of the
control dogs after challenge infection; the decline was
marked in three of the four dogs. Four of the ﬁve dogs that
were vaccinated with APR-1 did not show a similar decline,
and had Hb levels within (or very close to) the normal clinical
range of 12–14 gdl1. One dog (C5) from the vaccinated
group did become anemic (Hb concentration was 9.6 gdl1),
and this animal had more female worms (120 compared with
a mean of 88 female worms for the group) and more male
worms (87 compared with a mean of 80 male worms for the
group). However, using both Spearman and Pearson tests, we
did not detect a signiﬁcant correlation between worm
burdens (for either or both sexes) and Hb status of the
vaccinated dogs.

Figure 4. Vaccination with APR-1 Reduces Fecal Egg Counts of Dogs
after Challenge Infection with Hookworms
Statistically significant reduction (p ¼ 0.018) in median fecal egg counts
sampled on days 21, 23, and 26 of dogs vaccinated with APR-1 compared
to dogs that received adjuvant alone.
(A). Geometric mean values of fecal egg counts from vaccinated and
control dogs between challenge infection and necropsy.
(B). Error bars refer to the standard error of the mean.
DOI: 10.1371/journal.pmed.0020295.g004

counts into log values and ran the test in two ways: (1)
comparing the log transformed epgs in the last three egg
counts by analysis of variance (Kruskall-Wallis) revealed no
signiﬁcant differences among the groups for the last three egg
counts when each time point was considered individually; and
(2) comparing pooled data from the last three egg counts

Anti–APR-1 Antibodies Are Ingested by and Bind to the
Intestine of Feeding Hookworms
The site of anatomical expression of Ac-APR-1 within adult
hookworms has been previously reported by us to be the

Figure 5. Vaccination with APR-1 Reduces Adult Worm Burdens of Dogs after Challenge Infection with Hookworms
Statistically significant reduction at the p , 0.1 level (p ¼ 0.065) in median adult worm (both sexes) burdens of dogs vaccinated with APR-1 compared to
dogs that received adjuvant alone (A). Reductions are also shown when only male (B) (p ¼ 0.111) and only female (C) (p ¼ 0.1905) worms were
considered; however, statistically significant reductions were not achieved for single sex analyses. Bars represent the median value for each group.
DOI: 10.1371/journal.pmed.0020295.g005
PLoS Medicine | www.plosmedicine.org
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APR-1 antibodies were ingested with the blood-meal of the
worm and subsequently bound speciﬁcally to the intestine of
the parasite in situ.

IgG from Dogs Vaccinated with Ac-APR-1 Neutralizes
Proteolytic Activity In Vitro
Puriﬁed IgG from dogs that were immunized with Ac-APR-1
reduced the catalytic activity of the enzyme by 71%,
compared with just 6% reduction when an equivalent
amount of IgG from dogs immunized with adjuvant alone
was assessed (Table 1). The aspartic protease inhibitor,
pepstatin A, inhibits catalytic activity of APR-1 [23] and was
therefore used as a positive control to obtain 100% inhibition
for comparative purposes.

Figure 6. Vaccination of Dogs with APR-1 Reduces Blood Loss and
Protects against Anemia
Hb concentrations of vaccinated dogs were significantly (p ¼ 0.049)
greater than those of control dogs when blood was drawn after larval
challenge (0 and 7 d before necropsy [post]) but not when blood was
drawn 5 d before larval challenge (pre).
DOI: 10.1371/journal.pmed.0020295.g006

Discussion

microvillar surface of the gut [21,23]. To determine whether
vaccination of dogs induced circulating antibodies that
bound to the intestinal lumen during infection, parasites
were removed from vaccinated dogs, ﬁxed, sectioned, and
probed with anti-dog IgG conjugated to Cy3. Worms
recovered from dogs immunized with Ac-APR-1 but not from
dogs immunized with adjuvant alone reacted with Cy3conjugated anti-dog IgG (Figure 7), indicating that anti–

Here we describe protective vaccination of dogs with a
recombinant aspartic hemoglobinase, a pivotal enzyme in the
initiation of Hb digestion in the gut of canine hookworms
[12,21]. We show that APR-1 provides the best efﬁcacy thus
far reported for a recombinant vaccine aimed at reducing
hookworm egg counts, intestinal worm burdens, and hookworm-induced blood loss.
The vaccine efﬁcacy of recombinant Ac-APR-1 expressed in
baculovirus-infected insect cells was described earlier by us

Figure 7. Antibodies Bind In Situ to the Intestines of Hookworms that Feed on Vaccinated Dogs
Detection of antibodies that bound to the gut of worms recovered from vaccinated dogs (A and B) but not control dogs (C and D) by
immunofluorescence. Binding was detected using Cy3-conjugated rabbit anti-dog IgG, allowing only detection of antibodies that had bound in situ
while parasites were feeding on blood from vaccinated or control dogs. ic. intestinal contents; in, hookworm intestine; mv, intestinal microvillar surface;
ro, reproductive organs.
DOI: 10.1371/journal.pmed.0020295.g007
PLoS Medicine | www.plosmedicine.org
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The immunological parameters required for vaccineinduced protection against hookworm infection were, until
recently, poorly deﬁned. Protection against A. caninum by
vaccination of dogs with radiation-attenuated L3 was
reported many years ago [5]; however, it was not until
recently that murine [8,33] and canine [34] studies revealed
the protective mechanisms of the irradiated larval vaccine at
a cellular level. These studies suggested that a T-helper type-2
response is induced by vaccination with irradiated L3;
however the authors did not prove that a T-helper type-1
response abrogates protection. In our study reported here,
dogs vaccinated with APR-1 generated strong memory
responses to the recombinant antigen and did not secrete
Th-2 cytokines but instead secreted IFN-c in response to
stimulation with recombinant APR-1. Moreover, the dominant antibody isotype induced by vaccination was IgG2,
suggesting that a Th-1-like response was generated. Unlike
the clear association between IgG2 and type I cytokines such
as IFN-c in mice and humans, little is known about this
association in dogs. Experimental evidence using the canine
model suggests that immune responses (Th1 versus Th2) are,
however, linked to isotype production. For example, animals
infected with and protected against visceral leishmaniasis
(Th1 response) or Salmonella (also a Th1 response) mount a
higher IgG2 than IgG1 response [35,36]. Our data [34] show
that dogs immunized with irradiated hookworm larvae
demonstrated a stronger production of IgG1 (also supported
by [37]) which accompanied IL-4 production, implying a Th2
cytokine response in dogs is accompanied by the same
immunoglobulin isotypes seen in humans and mice. Based on
the current data, we cannot conclude that a Th-1 response to
APR-1 is required to obtain protection; however, it does not
inhibit the development of a protective memory response. It
should also be considered that successful immunity to the
different developmental stages of hookworms might require
very different immune response phenotypes, not unlike those
seen in schistosomiasis [38]. Further studies will explore the
effects of vaccination with APR-1 formulated with different
adjuvants and co-factors (e.g., cytokines) that will promote a
Th2 response.
Hematophagous helminths require blood as a source of
nutrients to mature and reproduce. Female schistosomes
ingest 13 times as many erythrocytes and ingest them about
nine times faster than male worms [39]. Moreover, mRNAs
encoding Hb-degrading proteases of schistosomes are overexpressed in female worms [40]. Although similar studies have
yet to be performed for hookworms, female hookworms are
bigger than males and lay up to 10,000 eggs per day, implying
that they have a greater metabolism and therefore greater
demand for erythrocytes. Ac-APR-1 degrades Hb in the gut
lumen of the worm, and it is therefore not surprising that
interruption of the function of APR-1 via the action of
neutralizing antibodies has a deleterious effect on the
establishment of worms, particularly females and their
subsequent egg production. We observed a similar (although
not as pronounced) phenomenon when dogs were vaccinated
with the cysteine hemoglobinase, Ac-CP-2, followed by
challenge infection with A. caninum L3 [22]. Vaccination with
CP-2, however, did not result in reduced adult worm burdens
or reduced blood loss, essential attributes of an efﬁcacious
hookworm vaccine.
Vaccination of livestock and laboratory animals with

Table 1. Reduction in Cleavage of the Fluorogenic Substrate oAminobenzoyl-IEF-nFRL-NH2 When 1.0 lg of Recombinant AcAPR-1 Was Pre-Incubated with 0.2 lg of IgG Purified from Sera of
Dogs Vaccinated with APR-1/AS03 or AS03 Alone (Control)
Protease and
Treatment

APR-1
APR-1
APR-1
APR-1

þ
þ
þ
þ

buffer
a-APR-1 IgG
control IgG
pepstatin

Corrected Relative
Fluorescence Units

Mean Percent
Reduction in Cleavage
of IEF-nFRL-NH2

362 6 13
104 6 24
340 6 41
0

0
71
6
100

Percent reductions caused by incubation of APR-1 with IgGs were determined using 1.0 lM pepstatin as positive
(100% reduction) control. Baseline was set at zero using the relative fluorescence of the positive control.
DOI: 10.1371/journal.pmed.0020295.t001

[24]; however, this initial vaccine trial was hampered by
limited availability of the recombinant protein: Suboptimal
doses were used and antibody responses (titers ,10,000) were
ﬁrst observed just 1 wk following the third (and ﬁnal)
immunization, and only in some dogs. Despite the weak
antibody responses, a statistically signiﬁcant reduction in
mean (18%, p , 0.05) and median (23%) hookworm burdens
were observed. In addition there was a shift of adult
hookworms from the small intestine to the colon [24].
However, no reduction in the mean fecal egg counts were
observed, and hematologic parameters were not assessed. The
improved immunogenicity of APR-1 observed in this study
might also be attributed to use of the adjuvant AS03
compared with alhydrogel in the previous study. We have
shown in a head-to-head comparison of a hookworm cysteine
hemoglobinase formulated with different adjuvants (including alhydrogel) that AS03-formulated protein generated
higher antibody titers and afforded greater protection to
vaccinated dogs [22]. In this study, we show that yeast-derived
APR-1 provides the best efﬁcacy thus far reported for a
recombinant vaccine aimed at reducing hookworm load and
potential transmission. Moreover, we show that vaccination
protects against the pathology associated with worm-induced
blood loss, or hookworm disease.
Hookworms bury their anterior ends into the intestinal
mucosa to feed, secreting anticoagulants to promote blood
ﬂow and stop clot formation at the site of attachment
(reviewed in [28]). Numerous anticoagulant peptides have
been reported from hookworms [29–31], and their combined
activities result in ‘‘leakage’’ of blood around the attachment
site and into the host intestine [32]. It is not known whether
the majority of blood loss during a hookworm infection is due
to leakage around the feeding site or from ingested blood
that enters the parasite’s alimentary canal for nutritional
purposes. To address this, attempts have been made to
measure blood lost from the anus of A. caninum (i.e., blood
that has passed through the parasite’s alimentary canal);
varying calculations have been proposed ranging from 0.14–
0.8 ml blood expelled over 24 h per adult worm (reviewed in
[32]). Whatever the true ﬁgure is, signiﬁcant blood loss occurs
via this route, supporting the hypothesis that vaccination with
APR-1 damages that parasite’s intestine and results in
decreased blood intake (and blood loss) by feeding worms.
PLoS Medicine | www.plosmedicine.org
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a hemoglobinase [23]. For this reason, we believe that APR-1
is now the major vaccine antigen from the adult stage of the
parasite, and as such, Na-APR-1 should undergo process
development and enter into Phase I clinical trials as a vaccine
for human hookworm infection. This vaccine strategy is now
being implemented for a larval hookworm antigen, with
Phase 1 human trials using ASP-2 formulated with Alhydrogel
already underway [49]. Based on the data reported here, APR1 may also be selected for downstream process development,
manufactured under good clinical manufacturing processes,
and tested in the clinic.

aspartic proteases of other nematodes, as well as trematode
helminths, has resulted in antifecundity/antiembryonation
effects. Immunization of sheep with the intestinal brush
border complex, H-gal-GP, confers high levels of protection
(both antiparasite and antifecundity) against H. contortus and
at least three different protease activities, including aspartic
proteases, have been detected in this extract [16,41].
Immunization of sheep with aspartic protease-enriched
fractions of H. contortus membranes resulted in 36%
reduction in adult worms and 48% reduction in fecal egg
output [17]. Vaccination of sheep with denatured H. contortus
proteases or recombinant proteases expressed in bacteria,
however, did not confer protection, suggesting that conformational epitopes are important in protection [17].
Vaccination of mice with recombinant aspartic protease of
the human blood ﬂuke, Schistosoma mansoni, resulted in 21%–
38% reduction in adult parasites after challenge with
infective cercariae; however a reduction in eggs deposited
in the liver (the cause of most pathology in schistosomiasis)
was not detected [42]. Protective efﬁcacy of aspartic proteases
has been observed against fungal pathogens as well. Vaccination of mice with secreted aspartic proteases of Candida
albicans, known virulence factors in candidiasis, protected
animals against a lethal challenge infection and inhibited
colonization of fungi in the kidneys [43]. Moreover, passive
transfer of serum from vaccinated animals conferred protection, pointing towards an antibody-mediated protective
mechanism.
Almost all of the pathology and morbidity of human
hookworm infection results from intestinal blood loss caused
by large numbers of adult hookworms. Depending on host
iron and protein stores, a range of hookworm intensities,
equivalent to burdens of 40 to 160 worms, is associated with
Hb levels below 11 gdl1, the World Health Organization
threshold for anemia. In Tanzania, Nepal, and Vietnam where
host iron stores are generally depleted, there is a direct
correlation between the number of adult hookworms in the
intestine and host blood loss [1,44]. Therefore the optimal
hookworm vaccine will be one that either prevents L3 from
developing into adult blood-feeding hookworms, or one that
blocks the establishment, survival, and fecundity of the adult
parasites in the intestine [3,45]. Achieving both goals will
likely require a vaccine cocktail comprised of an L3 antigen,
such as ASP-2 now under clinical development [46,47], and an
adult gut protease, such as APR-1.
An effective hookworm vaccine need not attain 100%
efﬁcacy. Unlike many unicellular organisms that reproduce
asexually within the host, nematodes need to sexually
reproduce. Therefore, small numbers of adult worms will
generate fewer eggs to contaminate the environment, and
subsequently reduce transmission. More importantly, because
hookworms are blood feeders, a partial reduction in adult
worm burden equates to a decrease in pathology, notably
iron-deﬁciency anemia [44]. Mathematical modeling of
schistosomiasis in China showed that elimination of the
parasite could be attained using an antifecundity vaccine that
targets egg output with 75% efﬁcacy [48], and it is likely that a
similar scenario applies to long-term elimination of soiltransmitted helminths such as hookworms. An orthologue of
Ac-APR-1 has been reported from the major human hookworm, N. americanus [23]. Na-APR-1 is structurally and
antigenically very similar to Ac-APR-1 and also functions as
PLoS Medicine | www.plosmedicine.org
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Patient Summary
Background Hookworms are parasites of the intestines. They can infect
many animals, including dogs, cats, and people. Worldwide, about one
person in five has a hookworm infection. Most of these one billion
people live in tropical countries. Hookworm is not spread from person to
person, because at one stage of its lifecycle, the parasite needs to be in
the soil. In areas where hookworm is common, people who have contact
with soil that contains human feces are at high risk of infection; because
children play on soil and often go barefoot, they have the greatest risk.
Infection leads to blood loss and a decrease in the amount of iron, and
this causes anemia (i.e., because of a lack of iron, the blood cannot carry
oxygen efficiently). There are effective drugs to treat the infection, but
they do not prevent the patient from becoming re-infected. Making a
vaccine against hookworm is therefore a priority. Some vaccines for use
in animals have already been developed, but their effectiveness is limited
to one stage of the hookworm’s lifecycle. The aim is to find a vaccine that
works against more than one of the stages that the parasite passes
through in its lifecycle.
What Did the Researchers Do and Find? The researchers focused on
two enzymes the parasite needs in order to live. Building on earlier
research and using a species of hookworm that affects dogs, the
researchers aimed to make these enzymes the ‘‘target’’ of a vaccine.
They first vaccinated dogs, then infected them with hookworm. These
dogs had fewer parasites than dogs that had not been vaccinated. Most
importantly, vaccinated dogs were protected against blood loss, and
most did not develop anemia. Laboratory tests confirmed that the target
enzymes had been damaged.
What Do These Findings Mean? This is the best result so far for a
hookworm vaccine used in dogs. The authors believe that, as well as
reducing parasite numbers, the vaccine reduces the ability of the
parasite to take in blood, which would explain the reduction in anemia.
The researchers have called for trials to begin with a vaccine targeted
against similar enzymes in the species of hookworm that most
commonly affects humans.
Where Can I Get More Information Online? The US Centers for Disease
Control have a fact sheet on hookworm:
http://www.cdc.gov/ncidod/dpd/parasites/hookworm/factsht_hookworm.
htm.
The Sabin Vaccine Institute has an overview of the Human Hookworm
Vaccine Initiative:
http://www.sabin.org/hookworm.htm.
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